ArticleArthritis research & therapy2026
Mesenchymal stem cells attenuate systemic sclerosis related lung fibrosis by inhibiting T follicular helper cells in tertiary lymphoid structure.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesThe aim of this study is to explore whether T follicular helper cells (Tfh) cells participate in the progression of systemic sclerosis related interstitial lung disease (SSc-ILD), and to observe whether mesenchymal stem cells (MSCs) therapy are able to regulate Tfh cells and the potential mechanism of treating SSc-ILD.
methodsThe expression of CXCR5+PD-1+CD4+T cells in SSc-ILD patients was verified by flow cytometry, immunohistochemistry and immunofluorescence. In vitro differentiated Tfh cells were cocultured with human lung fibroblasts. Peripheral blood mononuclear cells (PBMCs) were directly cocultured with MSCs. Naive CD4+ T cells isolated from PBMCs were cocultured with MSCs under Tfh cell-polarizing conditions. The percentage of CXCR5+PD-1+CD4+T cells, carboxyfluorescein succinimidyl ester (CFSE) fluorescence intensity and annexin V were determined by flow cytometric analysis. Bleomycin-induced SSc-ILD mice model received Bcl-6 inhibitor or MSCs treatment respectively. Then, the histopathology of lungs and pulmonary Tfh cells were examined in these mice.
resultsIncreased frequency of Tfh cells and intracellular IL-21 were found in SSc-ILD patients and positively correlated with mRSS. CXCR5+PD-1+ Tfh cells could drive the differentiation of myofibroblasts in vitro. Tertiary lymphoid structures (TLS), where Tfh cells localized, was found in lung biopsies from pulmonary fibrosis patients and BLM induced mice model. The upregulated frequency of Tfh cells and germinal center (GC) B cells were also found in the lung and spleen of BLM mice model. After depletion of Tfh cells, the proportion of GC B cells was reduced and the manifestation of lung fibrosis was attenuated. In addition, MSCs treatment contributed to remissive pulmonary fibrosis and reduced number of pulmonary TLS, followed by decreased frequency of Tfh cells both in lung of mice model and in peripheral circulation of SSc patients. In vitro, MSCs could downregulate the proportion of Tfh cells in SSc patients through suppressing their differentiation and proliferation.
conclusionTfh cells, which could promote fibrosis both in vivo and in vitro, play pivotal role in the pathogenesis of SSc-ILD. MSCs therapy can downregulate the percentage of Tfh cells and inhibit their proliferation and differentiation, which may be the mechanism for their effective treatment for SSc-ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.